Table 1 Baseline characteristics of patients*
From: Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes
Responder | Non-responder | Hazard ratio | P value | AUC | |
|---|---|---|---|---|---|
(N =17) | (N =26) | (95% CI) | |||
Male (%) | 64.7 | 61.5 | 0.85 (0.39-1.89) | 0.70 | NA |
Age (years) | 57.1 ± 12.2 | 61.9 ± 16.1 | 1.01 (0.98-1.04) | 0.63 | 0.62 |
Body mass index (kg/m2) † | 29.1 ± 9.8 | 29.5 ± 5.5 | 1.04 (0.98-1.10) | 0.21 | 0.66 |
Exenatide (%) | 58.8 | 65.4 | 1.56 (0.67-3.63) | 0.31 | NA |
Duration of diabetes (years) | 10.6 ± 8.6 | 14.8 ± 10.6 | 1.04 (0.99-1.08) | 0.051 | 0.62 |
Fasting C-peptide (ng/mL) | 2.4 ± 1.5 | 2.2 ± 1.1 | 0.91 (0.60-1.38) | 0.66 | 0.52 |
CPR6 (ng/mL)‡ | 4.0 ± 2.5 | 4.4 ± 2.4 | 1.05 (0.87-1.27) | 0.60 | 0.57 |
ΔCPR (ng/mL)§ | 1.5 ± 1.1 | 2.1 ± 1.5 | 1.15 (0.90-1.47) | 0.27 | 0.62 |
C-peptide index¶ | 1.8 ± 1.2 | 1.4 ± 0.7 | 0.79 (0.46-1.34) | 0.37 | 0.55 |
U-CPR (μg/day) | 87.2 ± 47.7 | 91.0 ± 71.1 | 1.00 (0.99-1.01) | 0.82 | 0.45 |
Preprandial glucose of the previous day GLP-1 initiated (mg/dL) | 162.6 ± 50.4 | 174.2 ± 36.9 | 1.00 (0.99-1.01) | 0.40 | 0.60 |
Average preprandial glucose level over 2 days after the initiation of GLP-1 receptor agonist treatment (mg/dL) | 140.0 ± 26.1 | 165.1 ± 31.8 | 1.01 (1.00-1.02) | 0.03 | 0.72 |
HbA1c (%) | 9.9 ± 1.8 | 9.7 ± 1.6 | 0.93 (0.74-1.16) | 0.51 | 0.49 |
Previous antidiabetic treatment (%) | |||||
Diet and/or metformin | 47.1 | 11.5 | 1.0 (Reference) | NA | |
Sulfonylurea | 23.5 | 38.5 | 5.0 (1.13-22.16) | 0.03 | NA |
Insulin | 29.4 | 50.0 | 5.3 (1.16-24.56) | 0.03 | NA |
Dose of insulin (unit) | 21.2 ± 5.9 | 26 ± 8.4 | NA | NA | NA |